Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proguanil + folic acid is a combination of two agents, proguanil (an antimalarial biguanide) and folic acid (a vitamin). Proguanil is used for the prevention and treatment of malaria, primarily by inhibiting the enzyme dihydrofolate reductase in Plasmodium species, thereby blocking DNA synthesis and cell multiplication in the parasite[2][5][6]. Folic acid is often co-administered with proguanil during pregnancy to prevent neural tube defects due to its role as an essential vitamin for DNA synthesis. The addition of folic acid does not enhance antimalarial efficacy but helps mitigate potential antifolate side effects on human cells. This combination may be used in special circumstances such as malaria prophylaxis during pregnancy when supplementation with high-dose folic acid is recommended alongside proguanil[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on proguanil + folic acid.